Dieckmann, Klaus-Peter, Pokrivcak, Tomas, Geczi, Lajos, Niehaus, David, Dralle-Filiz, Inken, Matthies, Cord, Dienes, Tamas, Zschaebitz, Stefanie, Paffenholz, Pia, Gschliesser, Tanja, Pichler, Renate, Mego, Michal, Bader, Pia, Zengerling, Friedemann, Heinzelbecker, Julia ORCID: 0000-0001-8993-7171, Krausewitz, Philipp, Krege, Susanne, Aurilio, Gaetano, Aksoy, Cem, Hentrich, Marcus, Seidel, Christoph, Toerzsoek, Peter, Nestler, Tim, Majewski, Matthaeus, Hiester, Andreas, Buchler, Tomas, Vallet, Sonia ORCID: 0000-0003-0146-8089, Studentova, Hana, Schoenburg, Sandra, Niedersuess-Beke, Dora, Ring, Julia, Trenti, Emanuela ORCID: 0000-0003-3034-531X, Heidenreich, Axel, Wuelfing, Christian, Isbarn, Hendrik, Pichlmeier, Uwe and Pichler, Martin (2022). Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study. Ther. Adv. Med. Oncol., 14. LONDON: SAGE PUBLICATIONS LTD. ISSN 1758-8359

Full text not available from this repository.

Abstract

Introduction: Clinical stage 1 (CS1) nonseminomatous (NS) germ cell tumors involve a 30% probability of relapse upon surveillance. Adjuvant chemotherapy with one course of bleomycin, etoposide, and cisplatin (1xBEP) can reduce this risk to <5%. However, 1xBEP results are based solely on five controlled trials from high-volume centers. We analyzed the outcome in a real-life population. Patients and Methods: In a multicentric international study, 423 NS CS1 patients receiving 1xBEP were retrospectively evaluated. Median follow-up was 37 (range, 6-89) months. Primary end points were relapse-free and overall survival evaluated after 5 years. We also looked at associations of relapse with clinico-pathological factors using stratified Kaplan-Meier methods and Cox regression models. Treatment modality and outcome of recurrences were analyzed descriptively. Results: The 5-year relapse-free survival rate was 96.2%. Thirteen patients (3.1%; 95% confidence interval, 1.65-5.04%) relapsed after a median time of 13 months, of which 10 were salvaged (77%). Relapses were mostly confined to retroperitoneal nodes. Three patients succumbed, two to disease progression and one to toxicity of chemotherapy. Pathological stage >pT2 was significantly associated with relapse rate. Conclusion: The relapse rate of 3.1% found in this population of NS CS1 patients treated with 1xBEP at the routine care level was not inferior to the median rate of 2.3% reported from a meta-analysis of controlled trials. Also, the cure rate of relapses of 77% is consistent with the previously reported rate of 80%. This study clearly shows that the 1xBEP regimen represents a safe treatment for NS CS1 patients.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Dieckmann, Klaus-PeterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pokrivcak, TomasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Geczi, LajosUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Niehaus, DavidUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Dralle-Filiz, InkenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Matthies, CordUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Dienes, TamasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Zschaebitz, StefanieUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Paffenholz, PiaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gschliesser, TanjaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pichler, RenateUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mego, MichalUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bader, PiaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Zengerling, FriedemannUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Heinzelbecker, JuliaUNSPECIFIEDorcid.org/0000-0001-8993-7171UNSPECIFIED
Krausewitz, PhilippUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Krege, SusanneUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Aurilio, GaetanoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Aksoy, CemUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hentrich, MarcusUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Seidel, ChristophUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Toerzsoek, PeterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Nestler, TimUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Majewski, MatthaeusUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hiester, AndreasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Buchler, TomasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Vallet, SoniaUNSPECIFIEDorcid.org/0000-0003-0146-8089UNSPECIFIED
Studentova, HanaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schoenburg, SandraUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Niedersuess-Beke, DoraUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ring, JuliaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Trenti, EmanuelaUNSPECIFIEDorcid.org/0000-0003-3034-531XUNSPECIFIED
Heidenreich, AxelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wuelfing, ChristianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Isbarn, HendrikUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pichlmeier, UweUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pichler, MartinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-698018
DOI: 10.1177/17588359221086813
Journal or Publication Title: Ther. Adv. Med. Oncol.
Volume: 14
Date: 2022
Publisher: SAGE PUBLICATIONS LTD
Place of Publication: LONDON
ISSN: 1758-8359
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
GERM-CELL TUMORS; LYMPH-NODE DISSECTION; RANDOMIZED CONTROLLED-TRIALS; LONG-TERM; EXTERNAL VALIDITY; CANCER SURVIVAL; FOLLOW-UP; CHEMOTHERAPY; MANAGEMENT; TESTISMultiple languages
OncologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/69801

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item